VIDEO: Two new glaucoma therapies continue down approval pathway

SAN DIEGO — At the Ophthalmology Innovation Summit here, Thomas A. Mitro, president and COO of Aerie Pharmaceuticals, discusses the company’s two glaucoma products in the pipeline. Rhopressa is currently in three phase 3 clinical trials, while Roclatan has completed phase 2b and the company plans to begin phase 3 trials in 2015.